Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeaStar Medical HoldingICU +0.63%31 EV-to-EBIT is -0.31 as of Aug. 04, 2026. GuruFocus rates ICU with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 386 Biotechnology companies, SeaStar Medical Holding ranks worse than 259067.1% on this metric.
SeaStar Medical Holding (NAS:ICU) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SeaStar Medical Holding's Enterprise Value for the quarter that ended in Mar. 2026 was $5.84 Mil.
SeaStar Medical Holding's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding EV-to-EBIT Related Terms
SeaStar Medical Holding EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SeaStar Medical Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's EV-to-EBIT falls into.
SeaStar Medical Holding's current Enterprise Value is $3.73 Mil.
SeaStar Medical Holding's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding (ICU) has a EV-to-EBIT of -0.31 as of Aug. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SeaStar Medical Holding and its competitors. According to the industry distribution chart, SeaStar Medical Holding ranks #999999 out of 386 companies in the Biotechnology industry.
Is SeaStar Medical Holding's EV-to-EBIT too high?
SeaStar Medical Holding's current EV-to-EBIT is -0.31. Based on the distribution chart, SeaStar Medical Holding ranks #999999 out of 386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SeaStar Medical Holding has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's EV-to-EBIT compare to TPST and OSRH?
According to the Biotechnology industry distribution chart, SeaStar Medical Holding ranks #999999 out of 386 companies for EV-to-EBIT. This places SeaStar Medical Holding in the lower half of its industry. The industry median EV-to-EBIT is 12.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.71, based on 386 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SeaStar Medical Holding and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SeaStar Medical Holding's current EV-to-EBIT is -0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current EV-to-EBIT of -0.31. The current EV-to-EBIT is -0.31. SeaStar Medical Holding's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current EV-to-EBIT is -0.31 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
31GF Score
Get the complete analysis for ICU
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICU has been successfully added to your 
